内皮祖细胞治疗肺动脉高压新进展-内科学专业毕业论文.pdfVIP

5 内皮祖细胞治疗肺动脉高压新进展 中文摘要 【摘 要】肺动脉高压 (Pulmonaryhypertension,P ) 是一种由已知或未知原因引 起的以肺血管收缩，重构，原位血栓形成为主要病变特征，导致肺血管阻力进行 性升高及血流受限，肺动脉压力异常升高的病理生理综合征，最终导致右心功能 损伤，甚至死亡。恢复血管内皮结构和功能的完整性，逆转肺血管重构，促进血 P 管新生替代永久性闭塞血管是治疗 的关键。近年来研究发现功能正常内皮祖细 胞 (Endothelialprogenitorcells,EPCs) 在维持血管内稳态、逆转肺血管重构及促进 血管新生方面有重要意义，可用于一些缺血性疾病的治疗，但一些病理状态下， EPCs功能发生异常，可能参与肺血管重构，促进PA 进展，本文就EPCs治疗P 的新进展做一综述。 【关键词】肺动脉高压；内皮祖细胞；治疗 1 Thenewprogressofendothelialprogenitorcellstreatmentof pulmonaryhypertension Abstract 【Abstract 】 Pulmonary hypertension is a disease characterized by pulmonary vasoconstriction, pulmonary vascular remodeling and in situ thrombosis, resulting in pulmonary vascular resistance increasing and blood flow restriction,pulmonary artery pressure elevating, eventually leading to right heart dysfunction, even death. Remedy of the integrity of endothelial structure and function, pulmonary vascular remodeling, angiogenesis replace permanent vascular occlusion, is the key to the treatment of PH. Recent studies have found that normal endothelial progenitor cells play an important role in maintaining vascular homeostasis and reversal pulmonary vascular remodeling and promote angiogenesis,can be used for the treatment of ischemic diseases. but some pathologic state, the function of EPCs dysfunction, may participate in the pulmonary vascular remodeling,promote the progress of pulmonary hypertension.Thisarticlemakesasummaryonthe EPCs forthetreatmentofP . Keywords pulmonaryhypertension;endothelialprogenitorcells;treatment 【 】 2 正 文 2013 5 P P 5